Monte Rosa Therapeutics, Inc. GLUE

11.77 0.05 0.43% as of 25 Sep
Market cap
$999.9M
P/E
0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
0.00 0.00 — — — — — —
P/S ratio
10.53 6.78 — — — — — —
P/FCF ratio
0.00 13.50 — — — — — —
P/Operating CF
(30.28) 3.98 — — — — — —
P/B ratio
5.59 2.30 — — — — — —
EV/Sales
7.48 1.86 — — — — — —
EV/EBITDA
0.00 0.00 — — — — — —
EV/FCF
(33.66) 3.70 — — — — — —
Current Ratio
6.12 2.40 5.07 10.79 20.96 1.49 2.27 —
Net Debt/EBITDA
8.22 5.10 1.70 2.43 4.89 1.52 (1.23) —
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 (1.56) —
ROE
(16.94%) (36.15%) (60.07%) (35.06%) (49.51%) 117.88% 25.43% —
ROA
(8.71%) (19.58%) (41.90%) (30.62%) (35.58%) (118.66%) (139.53%) —
ROIC
0.00% 0.00% 0.00% (920.94%) (3,154.52%) 0.00% 0.00% —
Return on Tangible Assets
(10.88%) (29.08%) (60.58%) (39.11%) (21.48%) (189.45%) (113.79%) —
Average Days of Receivables
34.24 0.84 0.00 0.00 — — — —
Earnings Yield
(2.93%) (14.70%) — — — — — —
Free Cash Flow Yield
(2.11%) 7.41% — — — — — —
Free Cash Flow per Share
(0.33) 0.51 (1.22) (2.23) (2.76) (17.43) (0.14) —
Book value per Share
2.81 3.02 3.49 5.75 13.90 (32.12) (0.28) —
Free Cash Flow
(27.50) 38.01 (62.78) (105.27) (69.02) (26.44) (6.17) —
EV/EBIT
0.00 0.00 — — — — — —
Other line items

Show all line items

Columns are period end dates